TABLE 1.
Patient background
| PD (n = 20) | Tremor group (n = 10) | Nontremor group (n = 10) | |
|---|---|---|---|
| Sex (M/F) | 8/12 | 4/6 | 4/6 |
| Age (years) | 70.4 ± 5.8 | 69.2 ± 5.4 | 71.6 ± 6.3 |
| Disease duration (years) | 5.6 ± 3.2 | 5.8 ± 3.6 | 5.6 ± 3.0 |
| Hoehn and Yahr stage | 2.6 ± 0.8 | 2.6 ± 1.0 | 2.7 ± 0.7 |
| MMSE | 26.4 ± 2.5 | 25.9 ± 2.8 | 26.6 ± 2.4 |
| Levodopa equivalent dose (mg/day) | 469.1 ± 261.3 | 460 ± 255.3 | 478.1 ± 280.7 |
| MDS‐UPDRS part I | 13.0 ± 5.3 | 14.0 ± 5.8 | 11.9 ± 4.9 |
| MDS‐UPDRS part III | 38.8 ± 14.3 | 38.8 ± 14.3 | 38.8 ± 14.3 |
| MDS‐UPDRS part IV | 4.7 ± 2.5 | 3.1 ± 1.2 | 6.2 ± 2.4** |
| PDQ‐8 mean index | 29.7 ± 22.1 | 43.4 ± 16.4 | 34.2 ± 10.8 |
| PDSS‐2 | 20.0 ± 9.6 | 25.2 ± 9.4 | 14.8 ± 6.6* |
| BDI‐II | 17.1 ± 8.6 | 20.6 ± 8.7 | 13.5 ± 7.1 |
Data are expressed as the mean ± SD (range)
BDI‐II, Beck depression inventory‐2; MDS‐UPDRS, Movement Disorder Society revision of the Unified PD Rating Scale; MMSE, Mini‐Mental State Examination; PDQ‐8, PD Questionnaire 8; PDSS‐2, PD Sleep Scale‐2.
*
p < .05; **p < .01.